Study register · detailSystematic Review · Sleep Disorders · 2022
Cannabis dosing and administration for sleep: a systematic review.
Velzeboer et al.·SleepImpact 0.6
MixedGRADEHigh42 citations
Samplek = 31 Studien
Durationunclear
ControlPlacebo or uncontrolled conditions
EndpointSleep quality
Blindingunklar
DesignSystematic Review
”Key finding
Subjective sleep improvements in approximately 37% of RCTs and 58% of uncontrolled studies, but no improvements in sleep architecture; benefit mainly in pain-related disorders, not in neurological, psychiatric or sleep disorders.
Summary
Systematic review on cannabis dosing and administration in sleep disorders; k=31 studies (19 RCTs, 12 uncontrolled studies). Sleep improvements in 7/19 RCTs and 7/12 uncontrolled studies. Strongest evidence for pain-related sleep disorders; subjective sleep quality improved, but no objective changes in sleep architecture. Most common side effects: headache, sedation, dizziness (dose-dependent).
P
PopulationPatients with sleep disorders as well as persons with pain-related, neurological or psychiatric conditions, pooled from 31 included studies
I
InterventionMedical cannabis (various cannabinoids incl. THC and CBD, various applications and dosages)
C
ControlPlacebo or uncontrolled conditions (depending on primary study)
O
OutcomeSleep improvements in 7/19 RCTs and 7/12 uncontrolled studies; no significant difference between THC and CBD; subjective sleep quality partly improved, sleep architecture not objectively improved
Confidence in the evidence
Very lowLowModerateHigh
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size★★★★★
Blinding—
Effect sizeMixed
Citations / year★★★★★
Authors
Velzeboer R, Malas A, Boerkoel P, Cullen K, Hawkins M, Roesler J, Lai WW
Study Objectives: As cannabis is increasingly used to treat sleep disorders, we performed a systematic review to examine the effects of cannabis on sleep and to guide cannabis prescribers in their recommendations to patients, specifically focusing on dosing.
Methods: We searched EMBASE, Medline, and Web of Science and identified 4550 studies for screening. Five hundred sixty-eight studies were selected for full-text review and 31 were included for analysis. Study results were considered positive based on improvements in sleep architecture or subjective sleep quality. Bias in randomized controlled trials was assessed using Cochrane Risk of Bias tool 2.0.
Results: Sleep improvements were seen in 7 out of 19 randomized studies and in 7 out of 12 uncontrolled trials. There were no significant differences between the effects of tetrahydrocannabinol and cannabidiol. Cannabis showed most promise at improving sleep in patients with pain-related disorders, as compared to those with neurologic, psychiatric, or sleep disorders, and showed no significant effects on healthy participants' sleep. While subjective improvements in sleep quality were often observed, diagnostic testing showed no improvements in sleep architecture. Adverse events included headaches, sedation, and dizziness, and occurred more frequently at higher doses, though no serious adverse events were observed.
Conclusion: High-quality evidence to support cannabis use for sleep remains limited. Heterogeneity in cannabis types, doses, timing of administration, and sleep outcome measures limit the ability to make specific dosing recommendations.